AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9806313 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium energy density (MED) diet (549 kJ/100 g)
Number of subjects: 6
Study 9806313 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy density (HED) diet (737 kJ/100 g)
Number of subjects: 6
Study 8536121 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fenoldopam (FNP)
Number of subjects: 183
Study 8536121 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (NTP)
Number of subjects: 183
Study 2375667 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE) three times per week for six weeks
Number of subjects: 24
Study 2375667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise beyond usual daily activities)
Number of subjects: 24
Study 333856 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5-40 mg)
Number of subjects: 11
Study 333856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31772085 — intervention group
Group type: EXPERIMENTAL
Intervention: SIDCER ICF
Number of subjects: 210
Study 31772085 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICF
Number of subjects: 210
Study 29200424 — intervention group
Group type: EXPERIMENTAL
Intervention: MeCFES assisted TOT (M‐TOT)
Number of subjects: 82
Study 29200424 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation care including TOT (C‐TOT)
Number of subjects: 82
Study 25785522 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cardiovascular component of the Sequential Organ Failure Assessment score
Number of subjects: 16386
Study 25785522 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular component of the Sequential Organ Failure Assessment score
Number of subjects: 16386
Study 25785522 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sequential Organ Failure Assessment score
Number of subjects: 16386
Study 25785522 — intervention group
Group type: COMPARATOR
Intervention: Existing Sequential Organ Failure Assessment score
Number of subjects: 16386
Study 23643372 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program offered in place of a semester of physical education classes
Number of subjects: 0
Study 23643372 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical education classes)
Number of subjects: 0
Study 20668835 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anatomical double-bundle hamstring tendons autograft
Number of subjects: 79
Study 20668835 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle bone-patellar tendon-bone autograft
Number of subjects: 79
Study 19221692 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine A (HupA), oral administration for 8-24 weeks at a dosage of 300-500 microg daily
Number of subjects: 4
Study 19221692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 17199237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissatisfied with performance of valued activities (n = 71)
Number of subjects: 206
Study 17199237 — intervention group
Group type: COMPARATOR
Intervention: Satisfied with performance of valued activities (n = 135)
Number of subjects: 206
Study 15347372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 400 microg b.i.d.
Number of subjects: 162
Study 15347372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 800 microg b.i.d.
Number of subjects: 162
Study 15347372 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 162
Study 11686218 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg twice daily
Number of subjects: 184
Study 11686218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 11284463 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 1268
Study 11284463 — intervention group
Group type: COMPARATOR
Intervention: sumatriptan 100 mg
Number of subjects: 1268
Study 8163058 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal microvascular hyperaemic response to local heating in subjects with fasting hyperglycaemia (1.01 [0.71-1.57]V, median and range)
Number of subjects: 22
Study 8163058 — intervention group
Group type: COMPARATOR
Intervention: Maximal microvascular hyperaemic response to local heating in control subjects (1.41 [1.32-2.13]V, p < 0.001)
Number of subjects: 22
Study 2971564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 15
Study 2971564 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S)
Number of subjects: 15
Study 2971564 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S) after pretreatment with Ipratropium bromide (IB)
Number of subjects: 15
Study 2971564 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S) after pretreatment with Salbutamol (S)
Number of subjects: 15
Study 2971564 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of Salbutamol (S) and Ipratropium bromide (IB)
Number of subjects: 15
Study 2971564 — intervention group
Group type: COMPARATOR
Intervention: Maximal effect of Salbutamol (S)
Number of subjects: 15
Study 2971564 — intervention group
Group type: COMPARATOR
Intervention: Maximal effect of Ipratropium bromide (IB)
Number of subjects: 15
Study 31611155 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) applied to respiratory muscles, 2 days a week for 6 weeks
Number of subjects: 27
Study 31611155 — intervention group
Group type: COMPARATOR
Intervention: Control group (Deep breathing exercises)
Number of subjects: 27
Study 30773576 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent high-frequency noise from dental equipment
Number of subjects: 90
Study 30773576 — intervention group
Group type: EXPERIMENTAL
Intervention: Working hours per week
Number of subjects: 90
Study 30773576 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (males vs females)
Number of subjects: 90
Study 30773576 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of experience
Number of subjects: 90
Study 30773576 — intervention group
Group type: EXPERIMENTAL
Intervention: Median count of severely affected hearing frequencies
Number of subjects: 90
Study 29188882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss (D)
Number of subjects: 388
Study 29188882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss plus exercise (D+E)
Number of subjects: 388
Study 29188882 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 388
Study 29188882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss (D) and Intensive diet-induced weight loss plus exercise (D+E)
Number of subjects: 388
Study 25795076 — intervention group
Group type: EXPERIMENTAL
Intervention: MPa200Z regimen (moxifloxacin, 200 mg pretomanid, and pyrazinamide)
Number of subjects: 207
Study 25795076 — intervention group
Group type: COMPARATOR
Intervention: HRZE regimen (isoniazid, rifampicin, PZA, and ethambutol)
Number of subjects: 207
Study 25795076 — intervention group
Group type: EXPERIMENTAL
Intervention: DRMPa200Z regimen (moxifloxacin, 200 mg pretomanid, and pyrazinamide for drug-resistant tuberculosis)
Number of subjects: 207
Study 25795076 — intervention group
Group type: EXPERIMENTAL
Intervention: MPa100Z regimen (moxifloxacin, 100 mg pretomanid, and pyrazinamide)
Number of subjects: 207
Study 25795076 — intervention group
Group type: EXPERIMENTAL
Intervention: MPa200Z regimen
Number of subjects: 207
Study 25795076 — intervention group
Group type: COMPARATOR
Intervention: HRZE regimen
Number of subjects: 207
Study 25795076 — intervention group
Group type: EXPERIMENTAL
Intervention: DRMPa200Z regimen
Number of subjects: 207
Study 23698396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg once daily
Number of subjects: 634
Study 23698396 — intervention group
Group type: COMPARATOR
Intervention: Exenatide 10 μg twice daily
Number of subjects: 634
Study 21593296 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide plus insulin in C‐peptide positive patients
Number of subjects: 29
Study 21593296 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide plus insulin in C‐peptide negative patients
Number of subjects: 29
Study 21593296 — intervention group
Group type: COMPARATOR
Intervention: Insulin monotherapy in C‐peptide negative patients
Number of subjects: 29
Study 21593296 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment
Number of subjects: 29
Study 19619705 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 533
Study 19619705 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 533
Study 16845354 — intervention group
Group type: EXPERIMENTAL
Intervention: Active involvement and intervention using early mobilization
Number of subjects: 0
Study 16845354 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention of rest and cervical collar immobilization
Number of subjects: 0
Study 12957683 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate
Number of subjects: 52
Study 12957683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 10953261 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0
Study 10953261 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9816131 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid (13cRA) treatment for 6 months
Number of subjects: 69
Study 9816131 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation during treatment
Number of subjects: 69
Study 9816131 — intervention group
Group type: COMPARATOR
Intervention: Normal bronchial biopsies
Number of subjects: 69
Study 1727833 — intervention group
Group type: COMPARATOR
Intervention: 19NT‐HPP alone (400 mg loading dose, followed by 200 mg every 3 weeks for 24 weeks)
Number of subjects: 24
Study 1727833 — intervention group
Group type: EXPERIMENTAL
Intervention: 19NT‐HPP with buserelin (3.3 or 6.6 mg implant after initial androgen suppression)
Number of subjects: 24
Study 6421140 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide, 200 mg twice daily
Number of subjects: 25
Study 6421140 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide, 150 mg 4 times daily
Number of subjects: 25
Study 6421140 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 25
Study 6421140 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 25
Study 6421140 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide and Disopyramide
Number of subjects: 25
Study 30689507 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV15-A
Number of subjects: 0
Study 30689507 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV15-B
Number of subjects: 0
Study 30689507 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 0
Study 28729180 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d)
Number of subjects: 795
Study 28729180 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (150 mg/d)
Number of subjects: 795
Study 26311707 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastic (TM, n=72) receiving daily a total dose of 1 g of crude CMG (330 mg capsules, tid)
Number of subjects: 156
Study 26311707 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free mastic (PFM, n=33) receiving daily a total dose of 1 g of polymer free mastic (330 mg caps, tid)
Number of subjects: 156
Study 26311707 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder mastic (PM, n=28) receiving daily a total dose of 2 g of crude CMG
Number of subjects: 156
Study 26311707 — intervention group
Group type: COMPARATOR
Intervention: Control group (C, n=23) receiving placebo
Number of subjects: 156
Study 24674455 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (45-min moderate-intensity workout)
Number of subjects: 6
Study 24674455 — intervention group
Group type: EXPERIMENTAL
Intervention: Food deprivation (24-hr period)
Number of subjects: 6
Study 22849509 — intervention group
Group type: EXPERIMENTAL
Intervention: Father inclusive intervention
Number of subjects: 533
Study 22849509 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 533
Study 20189092 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (lead-in phase)
Number of subjects: 427
Study 18595435 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 1 mg
Number of subjects: 65
Study 18595435 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 2 mg
Number of subjects: 65
Study 18595435 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 2.5 mg
Number of subjects: 65
Study 18595435 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 3 mg
Number of subjects: 65
Study 18595435 — intervention group
Group type: COMPARATOR
Intervention: zolpidem 10 mg
Number of subjects: 65
Study 11527889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone
Number of subjects: 290
Study 11527889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 9390614 — intervention group
Group type: EXPERIMENTAL
Intervention: I.V. fentanyl 2 microg/kg, followed by an infusion at the rate of 25 ng x kg(‐1) x min(‐1)
Number of subjects: 50
Study 9390614 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl injection and infusion at the same administration regimen as Group II
Number of subjects: 50
Study 9390614 — intervention group
Group type: COMPARATOR
Intervention: Bolus injections of both epidural and intravenous saline, followed by both epidural and I.V. infusions at the rate of 0.2 mL x kg(‐1) h(‐1)
Number of subjects: 50
Study 7955996 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes subjects
Number of subjects: 97
Study 7955996 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 97
Study 3116847 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy after conservative breast surgery plus irradiation
Number of subjects: 764
Study 3116847 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 764
Study 28382755 — intervention group
Group type: EXPERIMENTAL
Intervention: Small change behavioral weight loss intervention alone
Number of subjects: 405
Study 28382755 — intervention group
Group type: EXPERIMENTAL
Intervention: Small change behavioral weight loss intervention with positive affect/self‐affirmation (PA/SA)
Number of subjects: 405
Study 28382755 — intervention group
Group type: EXPERIMENTAL
Intervention: Small change PA/SA intervention
Number of subjects: 405
Study 28382755 — intervention group
Group type: COMPARATOR
Intervention: Small change approach alone
Number of subjects: 405
Study 28382755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 405
Study 25409287 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care (TOP)
Number of subjects: 265
Study 25409287 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 265
Study 23298183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 86
Study 23298183 — intervention group
Group type: COMPARATOR
Intervention: Equipment-based Pilates
Number of subjects: 86
Study 21910335 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy combined with thoracic injection of lentinan
Number of subjects: 60
Study 21910335 — intervention group
Group type: COMPARATOR
Intervention: Lentanian thoracically injected (Control)
Number of subjects: 60
Study 17512156 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management plus (CM+)
Number of subjects: 206
Study 17512156 — intervention group
Group type: COMPARATOR
Intervention: Contingency management (CM)
Number of subjects: 206
Study 16469112 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg/day (n = 144)
Number of subjects: 364
Study 16469112 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib 200 mg twice daily (n = 145)
Number of subjects: 364
Study 16469112 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 75)
Number of subjects: 364
Study 12846090 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined conservative treatment (antibacterial therapy, transcutaneous laser irradiation of the suprapubic region using intravesical methods)
Number of subjects: 60
Study 12846090 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined conservative treatment plus transurethral resection (TUR) of the urinary bladder mucosa
Number of subjects: 60
Study 12846090 — intervention group
Group type: COMPARATOR
Intervention: Control group (urodynamic tests: uroflowmetry, sphincterometry, electromyography of the urinary bladder muscles)
Number of subjects: 60
Study 10607324 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (4 weeks) followed by placebo (4 weeks)
Number of subjects: 50
Study 10607324 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin (8 weeks)
Number of subjects: 50
Study 9410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill test
Number of subjects: 55
Study 9410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairways running
Number of subjects: 55
Study 9410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation
Number of subjects: 55
Study 9410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloergometer test
Number of subjects: 55
Study 1283663 — intervention group
Group type: EXPERIMENTAL
Intervention: Malto-dextrin/glycine ORS
Number of subjects: 31
Study 1283663 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based ORS (WHO)
Number of subjects: 31
Study 29051989 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod 3.125 to 50 mg
Number of subjects: 0
Study 29051989 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod 25, 50, 75 mg
Number of subjects: 0
Study 29051989 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod 50 mg (multiple doses)
Number of subjects: 0
Study 29051989 — intervention group
Group type: COMPARATOR
Intervention: Iguratimod 50 mg (single dose)
Number of subjects: 0
Study 29051989 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod 50 mg (fed group)
Number of subjects: 0
Study 29051989 — intervention group
Group type: COMPARATOR
Intervention: Iguratimod 50 mg (fasted group)
Number of subjects: 0
Study 27077129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of autologous adipose-derived regenerative cells (ADRCs)
Number of subjects: 17
Study 27077129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of ADRCs in continent men
Number of subjects: 17
Study 27077129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of ADRCs in incontinent men
Number of subjects: 17
Study 26682224 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar trastuzumab
Number of subjects: 0
Study 26682224 — intervention group
Group type: COMPARATOR
Intervention: Reference product trastuzumab
Number of subjects: 0
Study 23817594 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (n = 27)
Number of subjects: 55
Study 23817594 — intervention group
Group type: COMPARATOR
Intervention: Sham condition (n = 28)
Number of subjects: 55
Study 20956838 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric pedometers
Number of subjects: 44
Study 20956838 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring‐levered pedometers
Number of subjects: 44
Study 20956838 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed (slower and faster)
Number of subjects: 44
Study 20956838 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with Down syndrome
Number of subjects: 44
Study 20956838 — intervention group
Group type: COMPARATOR
Intervention: Adults without a disability
Number of subjects: 44
Study 18303965 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 24 mg/day
Number of subjects: 417
Study 18303965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 16968509 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage with metal stent insertion
Number of subjects: 30
Study 16968509 — intervention group
Group type: COMPARATOR
Intervention: Surgical drainage procedure (choledochojejunostomy and gastrojejunostomy)
Number of subjects: 30
Study 12939735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial intervention
Number of subjects: 160
Study 12939735 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 160
Study 10689152 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka 3200)
Number of subjects: 200
Study 10689152 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka 8500)
Number of subjects: 200
Study 10689152 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka 41650)
Number of subjects: 200
Study 10689152 — intervention group
Group type: COMPARATOR
Intervention: Control group (Pneumo 23 vaccine)
Number of subjects: 200
Study 10689152 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (all groups)
Number of subjects: 200
Study 10689152 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine
Number of subjects: 200
Study 9490230 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of epistemological indicators during physiotherapy
Number of subjects: 20
Study 9490230 — intervention group
Group type: COMPARATOR
Intervention: Traditional physiotherapy methods
Number of subjects: 20
Study 1286054 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural meperidine
Number of subjects: 60
Study 1286054 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramuscular meperidine
Number of subjects: 60
Study 3889078 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocarboxazid
Number of subjects: 0
Study 3889078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31392213 — intervention group
Group type: EXPERIMENTAL
Intervention: Faroese chain dance intervention (twice‐weekly sessions for 6 weeks, 30 min for first 3 weeks, 45 min for last 3 weeks)
Number of subjects: 27
Study 31392213 — intervention group
Group type: EXPERIMENTAL
Intervention: Faroese chain dance intervention
Number of subjects: 27
Study 28856403 — intervention group
Group type: COMPARATOR
Intervention: Transurethral indwelling catheterization (TIC)
Number of subjects: 85